47 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27287367	36	Evaluation of bisbenzamidines as inhibitors for matriptase-2.	University of Bonn
27015008	51	Atropisomer Control in Macrocyclic Factor VIIa Inhibitors.	Bristol-Myers Squibb Research & Development
26985294	114	Design and Synthesis of Nonpeptide Inhibitors of Hepatocyte Growth Factor Activation.	Southern Research
27073051	71	Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group.	Bristol-Myers Squibb
26732532	69	Active site-directed plasmin inhibitors: Extension on the P2 residue.	Kobe Gakuin University
26704266	80	Novel phenylalanine derived diamides as Factor XIa inhibitors.	Bristol-Myers Squibb
26421993	44	Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors.	Aurigene Discovery Technologies
26367391	6	Phenylalanine and Phenylglycine Analogues as Arginine Mimetics in Dengue Protease Inhibitors.	Heidelberg University
26393374	34	Improving the Selectivity of Engineered Protease Inhibitors: Optimizing the P2 Prime Residue Using a Versatile Cyclic Peptide Library.	Queensland University of Technology
26114810	8	Synthesis of 3,4-diaminobenzoyl derivatives as factor Xa inhibitors.	Southeast University
26122211	3	Discovery of non-competitive thrombin inhibitor derived from competitive tryptase inhibitor skeleton: Shift in molecular recognition resulted from skeletal conversion of carboxylate into phosphonate.	Tokyo University of Pharmacy and Life Sciences
25592713	37	Pyridine and pyridinone-based factor XIa inhibitors.	Bristol-Myers Squibb
26151189	56	Structure-Based Design of Macrocyclic Coagulation Factor VIIa Inhibitors.	TBA
26005539	23	Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.	Bristol-Myers Squibb
25782055	9	Discovery of a Cyclic Boronic Acidß-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.	Rempex Pharmaceuticals
25881820	62	Design and synthesis of potent, selective phenylimidazole-based FVIIa inhibitors.	Bristol-Myers Squibb R & D
25728130	79	Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.	Bristol-Myers Squibb
24951330	25	Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.	Bristol-Myers Squibb
25523211	18	Identification of potent orally active factor Xa inhibitors based on conjugation strategy and application of predictable fragment recommender system.	Astellas Pharma
25438755	9	Novel strategy to boost oral anticoagulant activity of blood coagulation enzyme inhibitors based on biotransformation into hydrophilic conjugates.	Astellas Pharma
25405503	109	Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activity.	Bristol-Myers Squibb
25179681	81	Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.	Chinese Academy of Sciences
12565961	177	Structure-activity relationships of substituted benzothiophene-anthranilamide factor Xa inhibitors.	Berlex Biosciences
15887966	58	Synthesis and structure-activity relationships of novel selective factor Xa inhibitors with a tetrahydroisoquinoline ring.	Central Pharmaceutical Research Institute
12904065	30	Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.	Lg Life Sciences
11170646	106	Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.	Dupont Pharmaceuticals
10794696	233	Protease inhibitors: synthesis and QSAR study of novel classes of nonbasic thrombin inhibitors incorporating sulfonylguanidine and O-methylsulfonylisourea moieties at P1.	Universit£
9836616	92	Tetrahydro-isoquinoline-based factor Xa inhibitors.	Boehringer Mannheim
11858993	60	Novel, potent non-covalent thrombin inhibitors incorporating p(3)-lactam scaffolds.	Corvas International
16759084	12	Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors.	Peking University
16137886	88	Development of an oxazolopyridine series of dual thrombin/factor Xa inhibitors via structure-guided lead optimization.	Merck Research Laboratories
15501047	75	Chlorothiophenecarboxamides as P1 surrogates of inhibitors of blood coagulation factor Xa.	Merck
15341970	59	P4 and P1' optimization of bicycloproline P2 bearing tetrapeptidyl alpha-ketoamides as HCV protease inhibitors.	Eli Lilly
15203158	84	Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.	Merck
12482415	30	Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the 'distal binding pocket'.	Merck Research Laboratories
11960487	30	Structure-based design of novel potent nonpeptide thrombin inhibitors.	Boehringer Ingelheim Pharma
11689072	49	Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator.	Axys Pharmaceuticals
11549459	5	Synthesis and evaluation of the sunflower derived trypsin inhibitor as a potent inhibitor of the type II transmembrane serine protease, matriptase.	National Cancer Institute-Frederick
11425524	62	Dibasic inhibitors of human mast cell tryptase. Part 3: identification of a series of potent and selective inhibitors containing the benzamidine functionality.	Axys Pharmaceuticals
11266160	57	Synthesis and SAR of benzamidine factor Xa inhibitors containing a vicinally-substituted heterocyclic core.	Dupont Pharmaceuticals
11212109	14	The identification of alpha-ketoamides as potent inhibitors of hepatitis C virus NS3-4A proteinase.	Roche Discover Welwyn
9873692	54	Preparation of meta-amidino-N,N-disubstituted anilines as potent inhibitors of coagulation factor Xa.	Dupont Pharmaceuticals
9873397	37	In vitro evaluation and crystallographic analysis of a new class of selective, non-amide-based thrombin inhibitors.	3-Dimensional Pharmaceuticals
9871573	15	Discovery of LB30057, a benzamidrazone-based selective oral thrombin inhibitor.	Biotech Research Institute
9822554	14	1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase.	Bristol-Myers Squibb Pharmaceutical Research Institute
9804697	61	Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.	Northwestern University Medical School
9484495	74	Identification and initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation factor Xa.	Collegeville